Fisher & Paykel Healthcare's ROE % for the quarter that ended in Mar. 2026 was 24.85%. Fisher & Paykel Healthcare's PB Ratio for the quarter that ended in Mar. 2026 was 10.93.
Fisher & Paykel Healthcare's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 2.27%.
Fisher & Paykel Healthcare ROE % Adjusted to Book Value Related Terms
Fisher & Paykel Healthcare ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Fisher & Paykel Healthcare's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare ROE % Adjusted to Book Value Chart
FSPKF vs ISRG, BDX, MDLN: ROE % Adjusted to Book Value Comparison
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 2.27% mean?
Fisher & Paykel Healthcare (FSPKF) has a ROE % Adjusted to Book Value of 2.27% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Fisher & Paykel Healthcare and its competitors.
Is Fisher & Paykel Healthcare's ROE % Adjusted to Book Value too high?
Fisher & Paykel Healthcare's current ROE % Adjusted to Book Value is 2.27%. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's ROE % Adjusted to Book Value compare to ISRG and BDX?
Fisher & Paykel Healthcare's ROE % Adjusted to Book Value of 2.27% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current ROE % Adjusted to Book Value is 2.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (FSPKF) is currently considered Modestly Undervalued. The stock's GF Value™ is $27.38, compared to a current price of $22.52 — trading 17.8% below its estimated fair value. The current ROE % Adjusted to Book Value is 2.27%. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FSPKF), the current ROE % Adjusted to Book Value is 2.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FSPKF) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of $22.52 is trading 17.8% below its estimated GF Value™ of $27.38.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for FSPKF:
ROE % Adjusted to Book Value: 2.27%
GF Value™: $27.38 vs. price of $22.52 (17.8% below fair value)
No single metric tells the full story. See the FSPKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for FSPKF
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSPKF has been successfully added to your 
